Randomized Phase II study of the safety, efficacy and immune response of GVAX pancreas (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR). (4th November 2015)

• Record Type: Journal Article
• Authors: Le, Dung T; Crocenzi, Todd S; Urum, Jennifer N; Lutz, Eric R; Laheru, Daniel A; Sugar, Elizabeth A; Vonderheide, Robert H; Fisher, George A; Ko, Andrew H; Murphy, Aimee L; McDougall, Katherine; Ferber, Sandy; Brockstedt, Dirk G; Jaffee, Elizabeth M
• Is Part Of: Journal for immunotherapy of cancer. Volume 3(2015)Supplement 2
• Publication Date: 2015-11-04
• Subjects: Pancreatic Cancer -- Cyclophosphamide -- Pancreatic Cancer Cell -- Listeria -- Pancreatic Adenocarcinoma; Cancer -- Immunotherapy -- Periodicals; Cancer -- Immunological aspects -- Periodicals; Tumors -- Immunological aspects -- Periodicals; Immunotherapy -- Periodicals; 616.99406105
• DOI: 10.1186/2051-1426-3-S2-P155
• Languages: English
• ISSNs: 2051-1426